You are about to leave the Clinical Value website now.

Cancel

Precision Medicine

13 September 2024

Empowering Precision Oncology: Leveraging digital solutions to facilitate molecular tumour board meetings and patient care management

Cancer genomic testing | Jennifer’s story

Comprehensive genomic profiling (CGP) is a method of cancer genomic testing used to reveal the unique set of mutations within the cancer’s DNA which determine how…

READ MORE
22 May 2023

Next-generation sequencing (NGS) drives precision oncology in Singapore

In this article, Dr David Tan discusses the potential of NGS in Singapore, where the adoption of this technology is only just beginning to take root.

READ MORE
22 May 2023

NGS and precision oncology in South Korea: insights from Prof Kim Jee-Hyun

In this article, Prof Jee Hyun Kim explains her clinical experiences of NGS, and how she sees it evolving within South Korea’s innovative healthcare ecosystem.

READ MORE
22 May 2023

Breaking barriers to precision oncology implementation with digital solutions

While precision oncology has shown great promise, there are still barriers to its implementation, such as data fragmentation, staff shortages and time, funding, and lack of…

READ MORE
19 May 2023

Unlocking the Value of Quality Next-Generation Sequencing in APAC

This whitepaper shares recommendations on ensuring standardization and quality of NGS across the region, to realize the potential of NGS and establish more effective and market-appropriate…

READ MORE
19 May 2023

National Comprehensive Cancer Network (NCCN) guidelines for lung cancer

The NCCN Guidelines are a comprehensive set of guidelines detailing the sequential management decisions and interventions to assist in the decision-making process of individuals involved in…

READ MORE
19 May 2023

Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group

These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.

READ MORE

Be the first to receive updates, event opportunities, and thought leadership insights.